Products of Cartilage Metabolism

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 421-449

  Manicourt, Daniel Henri ^a   Devogelare, Jean Pierre ^b   Thonar, Eugene J M A ^c  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882557373     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50026-1     Document Type: Chapter

References (325)

1. Atencia L.J., McDevitt C.A., Nile W.B., Sokoloff L. Cartilage content of an immature dog. Connect Tissue Res. 1989, 18:235-242.
2. Poole A.R. Cartilage in health and disease. Arthritis and Allied Conditions. A Textbook of Rheumatology 2005, 223-269. Lippincott Williams and Wilkins, Philadelphia, PA. 15th ed. W.J. Koopman, L.W. Moreland (Eds.).
3. Mow V.C., Ratcliffe A. Structure and function of articular cartilage and meniscus. Basic Orthopaedic Biomechanics 1997, 113-177. Lippincott-Raven Press Publishers, Philadelphia, PA. 2nd ed. V.C. Mow, W.C. Hayes (Eds.).
4. Mow V.C., Wang C.C., Hung C.T. The extracellular matrix, interstitial fluid and ions as a mechanical signal transducer in articular cartilage. Osteoarthritis Cartilage 1999, 7:41-58.
5. Hing W.A., Sherwin A.F., Poole C.A. The influence of the pericellular microenvironment on the chondrocyte response to osmotic challenge. Osteoarthritis Cartilage 2002, 10:297-307.
6. Horikawa O., Nakajima H., Kikuchi T., Ichimura S., Yamada H., Fujikawa K., Toyama Y. Distribution of type VI collagen in chondrocyte microenvironment: study of chondrons isolated from human normal and degenerative articular cartilage and cultured chondrocytes. J. Orthop. Sci. 2004, 9:29-36.
7. Roughley P.J. Articular cartilage and changes in arthritis: noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage. Arthritis Res. 2001, 3:342-347.
8. Schwartz N.B., Domowicz M. Chondrodysplasias due to proteoglycan defects. Glycobiology 2002, 12:57R-68R.
9. Grimshaw M.J., Mason R.M. Modulation of bovine articular chondrocyte gene expression in vitro by oxygen tension. Osteoarthritis Cartilage 2001, 9:357-364.
10. Domm C., Schunke M., Christesen K., Kurz B. Redifferentiation of dedifferentiated bovine articular chondrocytes in alginate culture under low oxygen tension. Osteoarthritis Cartilage 2002, 10:13-22.
11. Semenza G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 2001, 7:345-350.
12. Coimbra I.B., Jimenez S.A., Hawkins D.F., Piera-Velazquez S., Stokes D.G. Hypoxia inducible factor-1 alpha expression in human normal and osteoarthritic chondrocytes. Osteoarthritis Cartilage 2004, 12:336-345.
13. Mason R.M., Sweeney C. The relationship between proteoglycan synthesis in Swarm chondrocytes and pathways of cellular energy and UDP-sugar metabolism. Carbohydrate Res. 1994, 255:255-270.
14. Lee R.B., Urban J.P. Functional replacement of oxygen by other oxidants in articular cartilage. Arthritis Rheum. 2002, 46:3190-3200.
15. Lee R.B., Wilkins R.J., Razaq S., Urban J.P. The effect of mechanical stress on cartilage energy metabolism. Biorheology 2002, 39:133-143.
16. Browning J.A., Wilkins R.J. Mechanisms contributing to intracellular pH homeostasis in an immortalised human chondrocyte cell line. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 2004, 137:409-418.
17. Urban J.P.G., Hall A.C., Ghel K.A. Regulation of matrix synthesis rates by the ionic and osmotic environment of articular chondrocytes. J. Cell. Physiol. 1993, 154:262-270.
18. Hall A.C., Starks I., Shoults C.L., Rashidbigi S. Pathways for K+ transport across the bovine articular chondrocyte membrane and their sensitivity to cell volume. Am. J. Physiol. 1996, 270(5 Pt 1):C1300-C1310.
19. Hopewell B., Urban J.P. Adaptation of articular chondrocytes to changes in osmolality. Biorheology 2003, 40:73-77.
20. Aydelotte M.B., Kuettner K.E. Heterogeneity of articular chondrocytes and cartilage matrix. Joint Cartilage Degradation. Basic and Clinical Aspects 1993, 37-65. M. Dekker Inc., New York. J.F. Woessner, D.S. Howell (Eds.).
21. Little C.B., Ghosh P., Bellenger C.R. Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep. J. Orthop. Res. 1996, 14:433-444.
22. Kim Y.J., Grodzinsky A.J., Plaas A.H. Compression of cartilage results in differential effects on biosynthetic pathways for aggrecan, link protein, and hyaluronan. Arch. Biochem. Biophys. 1996, 328:331-340.
23. Wong M., Siegrist M., Cao X. Cyclic compression of articular cartilage explants is associated with progressive consolidation and altered expression pattern of extracellular matrix proteins. Matrix Biol. 1999, 18:391-399.
24. Jin M., Frank E.H., Quinn T.M., Hunziker E.B., Grodzinsky A.J. Tissue shear deformation stimulates proteoglycan and protein biosynthesis in bovine cartilage explants. Arch. Biochem. Biophys. 2001, 395:41-48.
25. Sauerland K., Raiss R.X., Steimeyer J. Proteoglycan metabolism and viability of articular cartilage explants as modulated by the frequency of intermittent loading. Osteoarthritis Cartilage 2003, 11(5):343-350.
26. Muller F.J., Setton L.A., Manicourt D.H., Mow V.C., Howell D.S., Pita J.C. Centrifugal and biochemical comparison of proteoglycan aggregates from articular cartilage in experimental joint disuse and joint instability. J. Orthop. Res. 1994, 12:498-508.
27. Grumbles R.M., Howell D.S., Howard G.A., Roos B.A., Setton L.A., Mow V.C., Ratcliffe A., Muller F.J., Altman R.D. Cartilage metalloproteases in disuse atrophy. J. Rheumatol. 1995, 43(Suppl.):146-148.
28. Deschner J., Hofman C.R., Piesco N.P., Agarwal S. Signal transduction by mechanical strain in chondrocytes. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6:289-293.
29. Borrelli J., Tinsley K., Ricci W.M., Burns M., Karl I.E., Hotchkiss R. Induction of chondrocyte death and collagen damage in cyclically loaded articular cartilage. J. Orthop. Res. 2003, 21:888-898.
30. Kuhn K., D'Lima D.D., Hashimoto S., Lotz M. Cell death in cartilage. Osteoarthritis Cartilage 2004, 12:1-16.
31. Kurz B., Jin M., Patwari P., Cheng D.M., Lark M.W., Grodzinsky A.J. Biosynthetic response and mechanical properties of articular cartilage after injurious compression. J. Orthop. Res. 2001, 19:1140-1146.
32. Wilkins R.J., Browning J.A., Urban J.P. Chondrocyte regulation by mechanical load. Biorheology 2000, 37(1-2):67-74.
33. Lee R.B., Wilkins R.J., Razaq S., Urban J.P. The effect of mechanical stress on cartilage energy metabolism. Biorheology 2002, 39:133-143.
34. Mow V.C., Wang C.C., Hung C.T. The extracellular matrix, interstitial fluid and ions as a mechanical signal transducer in articular cartilage. Osteoarthritis Cartilage 1999, 7:41-58.
35. Guilak F., Mow V.C. The mechanical environment of the chondrocyte: a biphasic finite elment model of cell-matrix interactions in articular cartilage. J. Biomech. 2000, 33:1663-1673.
36. Sun D.D., Guo X.E., Likhitpanichkul M., Lai W.M., Mow V.C. The influence of the fixed negative charges on mechanical and electrical behaviors of articular cartilage under unconfined compression. J. Biomech. Eng. 2004, 126:6-16.
37. Vincent T.L., Hermannsson M.A., Hansen U.N., Amis A.A., Saklatvala J. Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded. Arthritis Rheum. 2004, 50:526-533.
38. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Bernan K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
39. Lee D.A., Noguchi T., Frean S.P., Lees P., Bader D.L. The influence of mechanical loading on isolated chondrocytes seeded in agarose constructs. Biorheology 2000, 37(1-2):149-161.
40. Hayashi T., Abe E., Yamate T., Taguchi Y., Jasin H. Nitric oxide production by superficial and deep articular chondrocytes. Arthritis Rheum. 1997, 40:261-269.
41. Hauselmann H.J., Stefanovic-Racic M., Michel B.A., Evans C.H. Differences in nitric oxide production by superficial and deep human articular chondrocytes: implications for proteoglycan turnover in inflammatory joint disease. J. Immunol. 1998, 160:1444-1448.
42. Poole A.R. Immunology of Cartilage. Osteoarthritis: Diagnosis and Medical/Surgical Management 1992, 155-189. W. B. Saunders Company, Philadelphia, PA. R. Moskowitz, D.S. Howell, V.M. Goldberg, H.J. Mankin (Eds.).
43. Ryan M.C., Sandell L.J. Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J. Biol. Chem. 1990, 265:10334-10339.
44. Aigner T., Zhu Y., Chansky H.H., Matsen F.A., Maloney W.J., Sandell L.J. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum. 1999, 42:1443-1450.
45. Nah H.D., Swoboda B., Birk D.E., Kirsch T. Type IIA procollagen: expression in developing chicken limb cartilage and human osteoarthritic articular cartilage. Dev. Dyn. 2001, 220:307-322.
46. Aurich M., Poole A.R., Reiner A., Mollenhauer C., Margulis A., Kuettner K.E., Cole A.A. Matrix homeostasis in aging normal human ankle cartilage. Arthritis Rheum. 2002, 46:2903-2910.
47. Fernandes R.J., Hirohata S., Engle J.M., Colige A., Cohn D.H., Eyre D.R., Apte S.S. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J. Biol. Chem. 2001, 276:31502-31509.
48. Li S-W., Sieron A.L., Fertala A., Hojima Y., Arnold W.V., Prockop D.J. The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc. Natl Acad. Sci. USA 1996, 93:5127-5130.
49. Rebuck N., Croucher L.J., Hollander A.P. Distribution of two alternatively spliced variants of the type II collagen N-propeptide compared with the C-propeptide in bovine chondrocyte pellet cultures. J. Cell. Biochem. 1999, 75:13-21.
50. Nelson F., Dahlberg L., Laverty S., Reiner A., Pidoux I., Ionescu M., Fraser G.L., Brooks E., Tanzer M., Rosenberg L.C., Dieppe P., Robin Poole A. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J. Clin. Invest. 1998, 102:2115-2125.
51. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Doggados M., Delmas P.D. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002, 46:2613-2624.
52. Carey D.E., Alini M., Ionescu M., Hyams J.S., Rowe J.C., Rosenberg L.C., Poole A.R. Serum content of the C-propeptide of the cartilage molecule type II collagen in children. Clin. Exp. Rheumatol. 1997, 15:325-328.
53. Shinmei M., Ito K., Matsuyama S., Yoshihara Y., Matsuzawa K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1993, 1:121-128.
54. Lohmander L.S., Yoshihara Y., Roos H., Kobayashi T., Yamada H., Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J. Rheumatol. 1996, 23:1765-1769.
55. Kobayashi T., Yoshihara Y., Samura A., Yamada H., Shinmei M., Roos H., Lohmander L.S. Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis. Ann. Rheum. Dis. 1997, 56:500-503.
56. Fraser A., Fearon U., Billinghurst R.C., Ionescu M., Reece R., Barwick T., Emery P., Poole A.R., Veale D.J. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003, 48:3085-3095.
57. Mansson B., Carey D., Alini M., Ionescu M., Rosenberg L.C., Poole A.R., Heinegard D., Saxne T. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J. Clin. Invest. 1995, 95:1071-1077.
58. Eyre D. Collagen of articular cartilage. Arthritis Res. 2002, 4:30-35.
59. Verzijl N., DeGroot J., Ben Z.C., Brau-Benjamin O., Maroudas A., Bank R.A., Mizrahi J., Schalkwijk C.G., Thorpe S.R., Baynes J.W., Bijlsma J.W., Lafeber F.P., TeKoppele J.M. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002, 46:114-123.
60. DeGroot J., Verzijl N., Wenting-van Wijk M.J., Jacobs K.M., Van El B., Van Roermund P.M., Bank R.A., Bijlsma J.W., TeKoppele J.M., Lafeber F.P. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum. 2004, 50:1207-1215.
61. Billinghurst R.C., Mwale F., Hollander A., Ionescu M., Poole A.R. Immunoassays for collagens in chondrocyte and cartilage explant cultures. Meth. Mol. Med. 2004, 100:251-274.
62. Barrett A.J. The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions 1978, 8:15-18.
63. Wu J.-J., Lark M.W., Chun L.E., Eyre D.R. Sites of stromelysin cleavage in collagen, II, IX, X and XI. J. Biol. Chem. 1991, 266:5625-5628.
64. Kozaci L.D., Buttle D.J., Hollander A.P. Degradation of type II collagen, but not proteoglycan correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. 1997, 40:164-174.
65. Nagase H. Activation on mechanisms of matrix metalloproteinases. Biol. Chem. 1997, 378:151-160.
66. van Meurs J., van Lent P., Holthuysen A., Lambrou D., Bayne E., Singer I., van den Berg W. Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for stromelysin-1 in cartilage destruction. J. Immunol. 1999, 163:5633-5639.
67. Poole A.R., Nelson F., Dahlberg L., Tchetina E., Kobayashi M., Yasuda T., Laverty S., Squires G., Kojima T., Wu W., Billinghurst R.C. Proteolysis of the collagen fibril in osteoarthritis. Biochem. Soc. Symp. 2003, 70:115-123.
68. Hollander A.P., Pidoux I., Reiner A., Rorabeck C., Bourne R., Poole A.R. Damage to type II collagen in aging and osteoarthrits starts at the articular surface, orginates around chondrocytes, and extends into the cartilage with progressive degeneration. J. Clin. Invest. 1995, 96:2859-2869.
69. Wu W., Billinghurst R.C., Pidoux I., Antoniou J., Zukor D., Tanzer M., Poole A.R. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase I and matrix metalloproteinase 13. Arthritis Rheum. 2002, 46:2087-2094.
70. Aurich M., Poole A.R., Reiner A., Mollenhauer C., Margulis A., Kuettner K.E., Coke A.A. Matrix homeostasis in aging normal human ankle cartilage. Arthritis Rheum. 2002, 46:2903-2910.
71. Dodge G.R., Poole A.R. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin-1. J. Clin. Invest. 1989, 83:647-661.
72. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., Van Wart H., Poole A.R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997, 99:1534-1545.
73. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 1996, 271:1544-1550.
74. Dahlberg L., Billinghurst R.C., Manner P., Nelson F., Webb G., Ionescu M., Reiner A., Tanzer M., Zukor D., Chen J., van Wart H.E., Poole A.R. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritc cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. 2000, 43:673-682.
75. Billinghurst R.C., Wu W., Ionescu M., Reiner A., Dahlberg L., Chen J., van Wart H., Poole A.R. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000, 43:664-672.
76. Bau B., Gebhard P.M., Haag J., Knorr T., Bartnik E., Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002, 46:2648-2657.
77. Neuhold L.A., Killar L., Zhao W., Sung M.L., Warner L., Kulik J., Turner J., Wu W., Billinghurst C., Meijers T., Poole A.R., Babij P., DeGennaro L.J. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 2001, 107:35-44.
78. Wu C.W., Tchetina E.V., Mwale F., Hasty K., Pidoux I., Reiner A., Chen J., Van Wart H.E., Poole A.R. Proteolysis involving matrix metalloproteinase 13 (collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J. Bone Miner. Res. 2002, 17:639-651.
79. Murphy G., Reynolds J.J. Extracellular matrix degradation. Connective Tissue and Its Heritable Disorders. Molecular Genetic and Medical Aspects 1993, 287-316. Wiley-Liss, New York. P.M. Royce, B. Steinmann (Eds.).
80. Kafienah W., Bromme D., Buttle D.J., Croucher L.J., Hollander A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J. 1998, 331(Pt 3):727-732.
81. Price J.S., Wang-Weigand S., Bohne R., Kozaci L.D., Hollander A.P. Retinoic acid-induced type II collagen degradation does not correlate with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. 1999, 42:137-147.
82. Brown N.L., Knott L., Halligan E., Yarram S.J., Mansell J.P., Sandy J.R. Microarray analysis of murine palatogenesis: temporal expression of genes during normal palate development. Dev. Growth Differ. 2003, 45:153-165.
83. Matyas J.R., Atley L., Ionescu M., Eyre D.R., Poole A.R. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum. 2004, 50:543-552.
84. Kojima T., Mwale F., Yasuda T., Girard C., Poole A.R., Laverty S. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum. 2001, 44:120-127.
85. Cerejo R., Poole A.R., Ionescu M., Lobanok T., Song J., Cahue S., Dunlop D., Sharma L. The association between cartilage collagenase activity measured in serum and progression of knee osteoarthritis in patients with and without evidence of generalized disease. Arthritis Rheum. 2002, 48(suppl 9):S144.
86. Henrotin Y., Deberg M., Dubuc J.E., Quettier E., Christgau S., Reginster J.Y. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004, 41:543-547.
87. Deberg M., Labasse A., Christgau S., Cloos P., Bang Henriksen D., Chapelle J.P., Zegels B., Reginster J.Y., Henrotin Y. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258-265.
88. Farrell A.J., Blake D.R., Palmer R.M., Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 1992, 51:1219-1222.
89. Hiran T.S., Moulton P.J., Hancock J.T. In situ detection of superoxide anions within procine articular cartilage. Br. J. Biomed. Sci. 1998, 55:199-203.
90. Henrotin Y.E., Zheng S.X., Deby G.P., Labasse A.H., Crielaard J.M., Reginster J.Y. Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. J. Rheumatol. 1998, 25:1595-1601.
91. Hashimoto S., Ochs R.L., Komiya S., Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum. 1998, 41:1632-1638.
92. Burkhardt H., Koller T., Engstrom A., Nandakumar K.S., Turnay J., Kraetsch H.G., Kalden J.R., Holmdahl R. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum. 2002, 46:2339-2348.
93. Mwale F., Billinghurst C., Wu W., Alini M., Webber C., Reiner A., Ionescu M., Poole J., Poole A.R. Selective assembly and remodelling of collagens II and IX associated with expression of the chondrocyte hypertrophic phenotype. Dev. Dyn. 2000, 218:648-662.
94. Sinigaglia L., Varenna M., Binelli L., Bartucci F., Arrigoni M., Ferrara R., Abbiati G. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 1995, 54:144-147.
95. Black D., Marabani M., Sturrock R.D., Robins S.P. Urinary excretion of hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1989, 48:641-644.
96. Seibel M.J., Duncan A., Robins S.P. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J. Rheumatol. 1989, 16:964-970.
97. Astbury C., Bird H.A., McLaren A.M., Robins S.P. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br. J. Rheumatol. 1994, 33:11-15.
98. Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem. J. 1988, 252:495-500.
99. MacDonald A.G., McHenry P., Robins S.P., Reid D.M. Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. Br. J. Rheumatol. 1994, 33:16-19.
100. Gough A.K.S., Peel N.F.A., Eastell R., Holder R.L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:14-17.
101. Garnero P., Delmas P.D. Biomarkers in osteoarthritis. Curr. Opin. Rheumatol. 2003, 15:641-646.
102. Eyre D.R., Atley L.M., Shao P., Vosberg-Smith K., Ochs V., Clemens J.D. Biochemical markers of bone and cartilage collagen degradation. Chemistry and Biology of Mineralized Tissues 2000, 347-350. American Academy of Orthopedic Surgeons, Rosemoat, IL. M. Goldberg, A. Boskey, C. Robinson (Eds.).
103. Christgau S., Gamero P., Fledelius C., Moniz C., Ensig M., Gineyts E., Rosenquist C., Qvist P. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
104. Atley L.M., Carlson K., Pietka T.A., Eyre D.R. Oncostatin M induces collagen degradation in human articular cartilage 2001, Osteoarthritis Research Society Intemational, Washington DC.
105. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003, 48:3130-3139.
106. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes B.W., Christgau S., Christiansen C., Uitterlinden A.G., Pols H.A. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004, 50:2471-2478.
107. Landewe R., Geusens P., Boers M., van der Heijde D., Lerns W., te Koppele J., van der Linden S., Garnero P. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1390-1399.
108. Mok S.S., Masuda K., Hauselmann H.J., Aydelotte M.B., Thonar E.J. Aggrecan synthesized by mature bovine chondrocytes suspended in alginate. Identification of two distinct metabolic matrix pools. J. Biol. Chem. 1994, 269:33021-33027.
109. Heinegard D., Lorenzo P., Sommarin Y. Articular cartilage matrix proteins. Osteoarthritic Disorders 1995, 229-237. American Academy of Orthopedic Surgeons Rosemont, LI. K.E. Kuettner, V.M. Goldberg (Eds.).
110. Maroudas A., Bayliss M.T., Uchitel-Kaushansky N., Schneiderman R., Gilay E. Aggrecan tumover in human articular cartilage use of aspartic acid racemization as a marker of molecular age. Arch. Biochem. Biophys. 1998, 350:61-71.
111. Ritz-Timme S., Collins M.J. Racemization of aspartic acid in human proteins. Ageing Res. Rev. 2002, 1:43-59.
112. van Kampen G.P., van de Stadt R.J., van de Laar M.A.F.J., van der Korst J.K. Two distinct metabolic pools of proteoglycans in articular cartilage. Articular Cartilage and Osteoarthritis 1992, 281-289. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
113. Bayliss M.T. Metabolism of animal and human osteoarthritic cartilage. Articular Cartilage and Osteoarthritis 1992, 487-500. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
114. Hauselmann H.J., Masuda K., Hunziker E.B., Neidhart M., Mok S.S., Michel B.A., Thonar E.J. Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage. Am. J. Physiol. 1996, 271(3 Pt 1):C742-C752.
115. Ilic M.Z., Robinson H.C., Handley C.J. Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage. Involvement of carboxyl-terminal processing in the catabolism of aggrecan. J. Biol. Chem. 1998, 273:17451-17458.
116. Loulakis P., Shrikhande A., Davis G., Maniglia C.A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem. J. 1992, 284(Pt 2):589-593.
117. Tortorella M., Pratta M., Liu R.Q., Abbaszade I., Ross H., Burn T., Amer E. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem. 2000, 275:25791-25797.
118. Tortorella M.D., Malfait A.M., Deccico C., Amer E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage de gradation. Osteoarthritis Cartilage 2001, 9:539-552.
119. Ratcliffe A.M., Doherty M., Maini R.N., Hardingham T.E. Increased levels of proteoglycan components in the synovial fluids of patients with acute joint disease. Ann. Rheum. Dis. 1988, 47:826-832.
120. Caroll G. Measurement of sulfated glycosaminoglycans and proteoglycan fragments in arthritic synovial fluid. Ann. Rheum. Dis. 1989, 48:17-24.
121. Thonar E.J-M.A., Manicourt D.H., Williams J.M., Fukuda K., Campion G.V., Sweet B.M.E., Lenz M.E., Schnitzer T.J., Kuettner K.E. Serum keratan sulfate: a measure of cartilage proteoglycan metabolism. Articular Cartilage and osteoarthritis 1992, 429-445. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
122. Dahlberg L., Roos H., Saxne T., Heinegard D., Lark M.W., Hoermer L.A., Lohmander L.S. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann. Rheum. Dis. 1994, 53:823-827.
123. Caterson B., Flannery C.R., Hughes C.E., Little C.B. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 2000, 19:333-344.
124. Elsaid K.A., Jay G.D., Chichester C.O. Detection of collagen type II and proteoglycans in the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates early damage to the articular cartilage matrix. Osteoarthritis Cartilage 2003, 11:673-680.
125. Sandy J.D., Neame P.J., Boynton R.E., Flannery C.R. Catabolism of aggrecan in cartilage explants identification of a major cleavage site within the interglobular domain. J. Biol. Chem. 1991, 266:8683-8685.
126. Lohmander L.S., Neame P.J., Sandy J.D. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury and osteoarthritis. Arthritis Rheum. 1993, 36:1214-1222.
127. Hughes C.E., Caterson B., Fosang A.J., Roughley P.J., Mort J.S. Monoclonal antibodies that specifically recognize neoepitope sequences generated by "aggrecanase" and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem. J. 1995, 305:799-804.
128. Lark M.W., Williams H., Hoemner L.A., Weidner J., Ayala J.M., Harper C.F., Christen A., Olszewski J., Konteatis Z., Webber R., Mumford R.A. Quantification of a matrix metalloprotein asegenerated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem. J. 1995, 307:245-252.
129. 374) is a primary event in proteolysis of the interglobular domain. J. Biol. Chem. 1995, 270:2550-2556.
130. Fosang A.J., Last K., Gardiner P., Jackson D.C., Brown L. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluid. Biochem. J. 1995, 310:337-343.
131. Singer I.I., Kawka D.W., Bayne E.K., Donatelli S.A., Weidner J.R., Williams H.A., Ayala J.M., Mumford R.A., Lark M.W., Glant T.T., Nabozny G.H., David C.S. VDIPEN, A metalloprotein asegenerated neoeptitope is induced and immunolocalized in articular cartilage during inflammatory arthritis. J. Clin. Invest. 1995, 95:2178-2186.
132. Fosang A.J., Last K., Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinases and aggrecanase activities can be independent. J. Clin. Invest. 1996, 98:2292-2299.
133. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoermer L.A., Hutchinson N.I., Singer I.I., Donatelli S.A., Weidner J.R., Williams H.R., Mumford R.A., Lohmander L.S. Aggrecan degradation in human cartilage. Evidence for both metalloproteinase and aggrecanase activity in normal, osteoarthritic and rheumatoid joints. J. Clin. Invest. 1997, 100:93-106.
134. Roberts C.R., Roughley P.J., Mort J.S. Degradation of human proteoglycan aggregate induced by hydrogen peroxide. Protein fragmentation, amino acid modification and hyaluronic acid cleavage. Biochem. J. 1989, 259:805-811.
135. Hie M.Z., Handley C.H., Robinson H.C., Mok M.T. Mechanism of catabolism of aggrecan by articular cartilage. Arch. Biochem. Biophys. 1992, 294:115-122.
136. Loulakis P., Shrikhande A., Davis G., Maniglia C.A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem. J. 1992, 284(Pt 2):589-593.
137. Rosenberg L., Wolfenstein-Todel C., Margolis R., Pal S., Strider W. Proteoglycans from bovine proximal humeral articular cartilage. Structural basis for the polydispersity of proteoglycan subunits. J. Biol. Chem. 1976, 251:6439-6444.
138. Heinegard D. Polydispersity of cartilage proteoglycans. Structural variation with size and buoyant density of the molecules. J. Biol. Chem. 1977, 252:1980-1989.
139. Bayliss M.T., Ali S.Y. Age-related differences in the composition and structure of human articular cartilage proteoglycans. Biochem. J. 1978, 176:683-693.
140. Morgelin M., Paulsson M., Hardingham T.E., Heinegard D., Engel J. Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy. Biochem. J. 1988, 253:175-185.
141. Sandy J.D., Plaas A.H., Koob T.J. Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring. Acta. Orthop. Scand. Suppl. 1995, 266:26-32.
142. Dudhia J., Davidson C.M., Wells T.M., Vynios D.H., Hardingham T.E., Bayliss M.T. Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem. J. 1996, 313(Pt 3):933-940.
143. Sandy J.D., Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADMTS) activity is responsible for the catabolic turnover and loss of whole aggrean whereas other protease activity is required for C-terminal processing in vivo. Biochem. J. 2001, 358(Pt 3):615-626.
144. Patwari P., Kurz B., Sandy J.D., Grodzinsky A.J. Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. Arch Biochem. Biophys. 2000, 374:79-85.
145. Flannery C.R., Lark M.W., Sandy J.D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J. Biol. Chem. 1992, 267(2):1008-1014.
146. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by Pump, gelatinases and cathepsin B. J. Biol. Chem. 1992, 267:19470-19474.
147. Fosang A.J., Last K., Knauper V., Murphy G., Neame P.J. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996, 380(1-2):17-20.
148. Mort J.S., Magny M.C., Lee E.R. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem. J. 1998, 335(Pt 3):491-494.
149. Little C.B., Flannery C.R., Hughes C.E., Mort J.S., Roughley P.J., Dent C., Caterson B. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem. J. 1999, 344(Pt 1):61-68.
150. Fosang A.J., Last K., Stanton H., Weeks D.B., Campbell I.K., Hardingham T.E., Hembry R.M. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J. Biol. Chem. 2000, 275(42):33027-33037.
151. Haseall V.C., Sandy J.D., Handley C.J. Regulation of proteoglycan metabolism in articular cartilage. Biology of the Synovial Joint 1999, 101-120. harwood Academic Publishers, The Netherlands. C.W. Archer, B. Caterson, M. Benjamin, J.R. Ralphs (Eds.).
152. Buttner F.H., Hughes C.E., Margerie D., Lichte A., Tschesche H., Caterson B., Bartnik E. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgglmut at the 'aggrecanase' and the MMP sites Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. Biochem. J. 1998, 333(Pt 1):159-165.
153. Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M., Liu R., Rosenfeld S.A., Copeland R.A., Decicco C.P., Wynn R., Rockwell A., Yang F., Duke J.L., Solomon K., George H., Bruckner R., Nagase H., Itoh Y., Ellis D.M., Ross H., Wiswall B.H., Murphy K., Hillman M.C., Hollis G.F., Newton R.C., Magolda R.L., Trzaskos J.M., Amer E.C. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999, 284:1664-1666.
154. Tortorella M.D., Pratta M., Liu R.Q., Austin J., Ross O.H., Abbaszade I., Burn T., Arner E. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J. Biol. Chem. 2000, 275:18566-18573.
155. Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J. Clin. Invest. 1992, 89:1512-1516.
156. Hu L.T., Eskildsen M.A., Masgala C., Steere A.C., Arner E.C., Pratta M.A., Grodzinsky A.J., Loening A., Perides G. Host metalloproteinases in Lyme arthritis. Arthritis Rheum. 2001, 44:1401-1410.
157. 374) is a primary event in proteolysis of the interglobular domain. J. Biol. Chem. 1995, 270:2550-2556.
158. Arner E.C., Pratta M.A., Trzaskos J.M., Decicco C.P., Tortorella M.D. Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J. Biol. Chem. 1999, 274:6594-6601.
159. Sugimoto K., Takahashi M., Yamamoto Y., Shimada K., Tanzawa K. Identifiation of aggrecanase activity in medium of cartilage culture. J. Biochem. (Tokyo) 1999, 126:449-455.
160. Pratta M.A., Tortorella M.D., Amer E.C. Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase. J. Biol. Chem. 2000, 275:39096-39102.
161. Sandy J.D., Thompson V., Doege K., Verscharen C. The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1. Biochem. J. 2000, 351(Pt 2):161-166.
162. Bayliss M.T., Hutton S., Hayward J., Maciewicz R.A. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the influence of age, topography and zone of tissue. Osteoarthritis Cartilage 2001, 9:553-560.
163. Chambers M.G., Cox L., Chong L., Suri N., Cover P., Bayliss M.T., Mason R.M. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum 2001, 44:1455-1465.
164. Lee E.R., Lamplugh L., Davoli M.A., Beauchemin A., Chan K., Mort J.S., Leblond C.P. Enzymes active in the areas undergoing cartilage resorption during the development of the secondary ossification center in the tibiae of rats ages 0-21 days: I. Two groups of proteinases cleave the core protein of aggrecan. Dev Dyn. 2001, 222:52-70.
165. Sztrolovics R., Alini M., Roughley P.J., Mort J.S. Aggrecan degradation in human intervertebral dise and articular cartilage. Biochem. J. 1997, 326(Pt 1):235-241.
166. Mercuri F.A., Maciewicz R.A., Tart J., Last K., Fosang A.J. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J. Biol. Chem. 2000, 275:33038-33045.
167. Westling J., Fosang A.J., Last K., Thompson V.P., Tomkinson K.N., Hebert T., McDonagh T., Collins-Racie L.A., LaVallie E.R., Morris E.A., Sandy J.D. ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase sit (Asn341-Phe342) in the aggrecan interglobular domain. J. Biol. Chem. 2002, 277:16059-16066. Epub 2002 Feb 19.
168. Little C.B., Hughes C.E., Curtis C.L., Janusz M.J., Bohne R., Wang-Weigand S., Taiwo Y.O., Mitchell P.G., Otterness I.G., Flannery C.R., Caterson B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 2002, 21:271-288.
169. van Meurs J.B., van Lent P.L., Holthuysen A.E., Singer I.I., Bayne E.K., van den Berg W.B. Kinetics of aggrecanase-and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum. 1999, 42:1128-1139.
170. van Meurs J., van Lent P., Stoop R., Holthuysen A., Singer I., Bayne E., Mudgett J., Poole R., Billinghurst C., van der Kraan P., Buma P., van den Berg W. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum 1999, 42:2074-2084.
171. van Meurs J.B., van Lent P.L., van de Loo A.A., Holthuysen A.E., Bayne E.K., Singer I.I., van den Berg W.B. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann. Rheum. Dis. 1999, 58:350-356.
172. Pratta M.A., Yao W., Decicco C., Tortorella M.D., Liu R.Q., Copeland R.A., Magolda R., Newton R.C., Trzaskos J.M., Amer E.C. Aggrecan protects cartilage collagen from proteolytic cleavage. J. Biol. Chem. 2003, 278:45539-45545. Epub 2003 Ju 130.
173. Flannery C.R., Little C.B., Hughes C.E., Caterson B. Expression of ADAMTS homologues in articular cartilage. Biochem. Biophys. Res. Commun. 1999, 260:318-322.
174. Koshy P.J., Lundy C.J., Rowan A.D., Porter S., Edwards D.R., Hogan A., Clark I.M., Cawston T.E. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002, 46:961-967.
175. Sylvester J., Liacini A., Li W.Q., Zafarullah M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, ?13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal. 2004, 16:469-476.
176. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., Brockbank S.M., Edwards D.R., Parker A.E., Clark I.M. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.
177. Curtis C.L., Hughes C.E., Flannery C.R., Little C.B., Harwood J.L., Caterson B. n?3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J. Biol. Chem. 2000, 275:721-724.
178. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositolanchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 2004, 279:10042-10051. Epub 2003 Dec 29.
179. Gao G., Westling J., Thompson V.P., Howell T.D., Gottschall P.E., Sandy J.D. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J. Biol. Chem. 2002, 277:11034-11041. Epub 2002 Jan 16.
180. Hashimoto G., Shimoda M., Okada Y. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J. Biol Chem. 2004, 279:32483-32491. Epub 2004 May 25.
181. Flannery C.R., Zeng W., Corcoran C., Collins-Racie L.A., Chockalingam P.S., Hebert T., Mackie S.A., McDonagh T., Crawford T.K., Tomkinson K.N., LaVallie E.R., Morris E.A. Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J. Biol. Chem. 2002, 277:42775-42780. Epub 2002 Aug 28.
182. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci. 2002, 115(Pt 19):3719-3727.
183. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 2001, 276:12501-12504. Epub 2001 Jan 23.
184. Rodriguez-Manzaneque J.C., Westling J., Thai S.N., Luque A., Knauper V., Murphy G., Sandy J.D., Iruela-Arispe M.L. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. 2002, 293:501-508.
185. Tortorella M.D., Arner E.C., Hills R., Easton A., Korte-Sarfaty J., Fok K., Wittwer A.J., Liu R.Q., Malfait A.M. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J. Biol. Chem. 2004, 279:17554-17561. Epub 2004 Jan 07.
186. Plaas A.H., Wong-Palms S., Roughley P.J., Midura R.J., Hascall V.C. Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan. J. Biol. Chem. 1997, 272:20603-20610.
187. Bayliss M.T., Osborne D., Woodhouse S., Davidson C. Sulfation of chondroitin sulfate in human articular cartilage. The effect of age-topographical position, and zone of cartilage on tissue composition. J. Biol. Chem. 1999, 274:15892-15900.
188. Plaas A.H., West L.A., Wong-Palms S., Nelson F.R. Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate. J. Biol. Chem. 1998, 273:12642-12649.
189. van den Berg W.B., van der Kraan P.M., Scharstuhl A., van Beuningen H.M. Growth factors and cartilage repair. Clin. Orthop. 2001, (391 Suppl):S244-S250.
190. Martel-Pelletier J., Alaaeddine N., Pelletier J.P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999, 4:D694-D703.
191. Sauerland K., Plaas A.H., Raiss R.X., Steinmeyer J. The sulfation pattern of chondroitin sulfate from articular cartilage-explants in response to mechanical loading. Biochim. Biophys. Acta. 2003, 1638:241-248.
192. Caterson B., Hughes C.E., Johnstone B., Mort J.S. Immunological markers of cartilage proteoglycan metabolism in animal and human osteoarthritis. Articular Cartilage and Osteoarthritis 1992, 415-427. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
193. Visco D.M., Johnstone B., Hill M.A., Jolly G.A., Caterson B. Immunohistochemical analysis of 3-B-(?) and 7-D-4 epitope expression in canine osteoarthritis. Arthritis Rheum. 1993, 36:1718-1725.
194. Slater R.R., Bayliss M.T., Lachiewicz P.F., Visco D.M., Caterson B. Monoclonal antibodies that detect biochemical markers of arthritis in humans. Arthritis Rheum. 1995, 38:655-659.
195. Hazell P.K., Dent C., Fairclough J.A., Bayliss M.T., Hardingham T.E. Changes in glycosaminoglycan epitope levels in knee joint fluid following injury. Arthritis Rheum. 1995, 38:953-959.
196. Bautch J.C., Clayton M.K., Chu Q., Johnson K.A. Synovial fluid chondroitin sulphate epitopes 3B3 and 7D4, and glycosaminoglycan in human knee osteoarthritis after exercise. Ann. Rheum. Dis. 2000, 59:887-891.
197. Poole A.R. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum. Dis. Clin. North. Am. 2003, 29:803-818.
198. Poole A.R., Ionescu M., Swan A., Dieppe P.A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. J. Clin. Invest. 1994, 94:25-33.
199. Carlson C.S., Loeser R.F., Johnstone B., Tulli H.M., Dobson D.B., Caterson B. Osteoarthritis in cynomolgus macaques II. Detection of modulated preoteoglycan epitopes in cartilage and synovial fluid. J. Orthop. Res. 1995, 13:399-409.
200. Belcher C., Yaqub R., Fawthrop F., Bayliss M., Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann. Rheum. Dis. 1997, 56:299-307.
201. Fawthrop F., Yaqub R., Belcher C., Bayliss M., Ledingham J., Doherty M. Chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in progressive versus nonprogressive osteoarthritis. Ann. Rheum. Dis. 1997, 56:119-122.
202. Thonar E.J-M.A., Manicourt D.H., Williams J.M., Fukuda K., Campion G.V., Sweet B.M.E., Lenz M.E., Schnitzer T.J., Kuettner K.E. Serum keratan sulfate: a measure of cartilage proteoglycan metabolism. Articular Cartilage and Osteoarthritis 1992, 429-445. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
203. Webber C., Glant T.T., Roughley P.J., Poole A.R. The identification and characterization of two populations of aggregating proteoglycans of high buoyant density isolated from post-natal human articular cartilages of different ages. Biochem. J. 1987, 248:735-740.
204. Scott J.E. Oxygen and the connective tissues. T I B S 1992, 17:340-343.
205. Manicourt D-H., Pita J.C., Thonar E.J-M., Howell D.S. Proteoglycans non-dissociatively extracted from different zones of canine normal articular cartilage: variations in the sedimentation profile of aggrecan with degree of physiological stress. Connect. Tissue Res. 1991, 26:231-246.
206. Sweet M.B., Thonar E.J., Immelman A.R., Solomon L. Biochemical changes in progressive osteoarthrosis. Ann. Rheum. Dis. 1977, 36:387-398.
207. Brown G.M., Huckerby T.N., Bayliss M.T., Nieduszynski I.A Human aggrecan keratan sulfate undergoes structural changes during adolescent development. J. Biol. Chem. 1998, 273:26408-26414.
208. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 1999, 274:18843-18846.
209. Burton-Wurster N., Liu W., Matthews G.L., Lust G., Roughley P.J., Glant T.T. Cs-Szabo G. TGF beta 1 and biglycan, decorin, and fibromodulin metabolism in canine cartilage. Osteoarthritis Cartilage 2003, 11:167-176.
210. Knudson C.B., Knudson W. Cartilage proteoglycans. Semin. Cell Dev. Biol. 2001, 12:69-78.
211. Danielson K.G., Baribault H., Holmes D.F., Graham H., Kadler K.E., Iozzo R.V. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell. Biol. 1997, 136:729-743.
212. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., Satomura K., Dominguez P., Zhao C., Kulkarni A.B., Robey P.G., Young M.F. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet. 1998, 20:78-82.
213. Kashiwagi M., Enghild J.J., Gendron C., Hughes C., Caterson B., Itoh Y., Nagase H. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J. Biol. Chem. 2004, 279:10109-10119. Epub 2003 Dec 08.
214. Poole A.R., Rosenberg L.C., Reiner A., Ionescu M., Bogoch E., Roughley P.J. Contents and distributions of the proteoglycans decorin and biglycan in normal and osteoarthritic human articular cartilage. J. Orthop. Res. 1996, 14:681-689.
215. Cs-Szabo G., Roughley P.J., Plaas A.H., Glant T.T. Large and small proteoglycans of osteoarthritic and rheumatoid articular cartilage. Arthritis Rheum. 1995, 38:660-668.
216. Cs-Szabo G., Melching L.I., Roughley P.J., Glant T.T. Changes in messenger RNA and protein levels of proteoglycans and link protein in human osteoarthritic cartilage samples. Arthritis Rheum. 1997, 40:1037-1045.
217. Bock H.C., Michaeli P., Bode C., Schultz W., Kresse H., Herken R., Miosge N. The small proteoglycans decorin and biglycan in human articular cartilage of late-stage osteoarthritis. Osteoarthritis Cartilage 2001, 9:654-663.
218. Polgar A., Falus A., Koo E., Ujfalussy I., Sesztak M., Szuts I., Konrad K., Hodinka L., Bene E., Meszaros G., Ortutay Z., Farkas E., Paksy A., Buzas E.I. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford) 2003, 42:522-527.
219. Melching L.I., Roughley P.J. Modulation of keratan sulfate synthesis on lumican by the action of cytokines on human articular chondrocytes. Matrix Biol. 1999, 18:381-390.
220. Bengtsson E., Neame P.J., Heinegard D., Sommarin Y. The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues. J. Biol. Chem. 1995, 270:25639-25644.
221. Bengtsson E., Morgelin M., Sasaki T., Timpl R., Heinegard D., Aspberg A. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J. Biol. Chem. 2002, 277:15061-15068. Epub 2002 Feb 14.
222. SundarRaj N., Fite D., Ledbetter S., Chakravarti S., Hassell J.R. Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. J. Cell Sci. 1995, 108(Pt 7):2663-2672.
223. Nicole S., Davoine C.S., Topaloglu H., Cattolico L., Barral D., Beighton P., Hamida C.B., Hammouda H., Cruaud C., White P.S., Samson D., Urtizberea J.A., Lehmann-Horn F., Weissenbach J., Hentati F., Fontaine B. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000, 26:480-483.
224. Arikawa-Hirasawa E., Watanabe H., Takami H., Hassell J.R., Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat. Genet. 1999, 23:354-358.
225. Costell M., Gustafsson E., Aszodi A., Morgelin M., Bloch W., Hunziker E., Addicks K., Timpl R., Fassler R. Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 1999, 147:1109-1122.
226. Handler M., Yurchenco P.D., Iozzo R.V. Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 1997, 210:130-145.
227. French M.M., Smith S.E., Akambi K., Sanford T., Hecht J., Farach-Carson M.C., Carson D.D. Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol. 1999, 145:1103-1115.
228. Kou I., Ikegawa S. SOX9-dependent and -independent transcriptional regulation of human cartilage link protein. J. Biol. Chem. 2004, 279:50942-50948. Epub 2004 Sep 28.
229. Seguin C.A., Bemier S.M. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: Role of MEK1/2 and NF-kappaB signaling pathways. J. Cell. Physiol. 2003, 197:356-369.
230. Fitzgerald J.B., Jin M., Dean D., Wood D.J., Zheng M.H., Grodzinsky A.J. Mechanical compression of cartilage explants induces multiple time-dependent gene expression patterns and involves intracellular calcium and cyclic AMP. J. Biol. Chem. 2004, 279:19502-19511. Epub 2004 Feb 11.
231. Bolton M.C., Dudhia J., Bayliss M.T. Age-related changes in the synthesis of link protein and aggrecan in human articular cartilage: implications for aggregate stability. Biochem. J. 1999, 337(Pt 1):77-82.
232. Roughley P.J., Nguyen Q., Mon J.S. The role of proteinases and oxygen radicals in the degradation of human articular cartilage. Articular Cartilage and Osteoarthritis 1992, 305-317. Raven Press, New York. K.E. Kuetmer, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
233. Mwale F., Demers C.N., Petit A., Roughley P., Poole A.R., Steffen T., Aebi M., Antoniou J. A synthetic peptide of link protein stimulates the biosynthesis of collagens, II, IX and proteoglycan by cells of the intervenebral disc. J. Cell. Biochem. 2003, 88:1202-1213.
234. Dean M.F., Sansom P. Link peptide cartilage growth factor is degraded by membrane proteinases. Biochem J. 2000, 349(Pt 2):473-479.
235. McKenna L.A., Liu H., Sansom P.A., Dean M.F. An N-terminal peptide from link protein stimulates proteoglycan biosynthesis in human articular cartilage in vitro. Arthritis Rheum. 1998, 41:157-162.
236. Liu H., McKenna L.A., Dean M.F. An N-terminal puptide from link protein can stimulate biosynthesis of collagen by human articular cartilage. Arch. Biochem. Biophys. 2000, 294:115-122.
237. Goodstone N.J., Doran M.C., Hobbs R.N., Butler R.C., Dixey J.J., Ashton B.A. Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Ann. Rheum. Dis. 1996, 55:40-46.
238. Guerassimov A., Duffy C., Zhang Y., Banerjee S., Leroux J.Y., Reimann A., Webber C., Delaunay N., Vipparti V., Ronbeck L., Cartman A., Arsenault L., Rosenberg L.C., Poole A.R. Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis. J. Rheumatol. 1997, 24:959-964.
239. Guerassimov A., Zhang Y., Banerjee S., Cartman A., Webber C., Esdaile J., Fitzcharles M.A., Poole A.R. Autoimmunity to cartilage link protein in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 1998, 25:1480-1484.
240. Guerassimov A., Zhang Y., Cartman A., Rosenberg L.C., Esdaile J., Fitzcharles M.A., Poole A.R. Immune responses to cartilage link protein and the GI domain of proteoglycan aggrecan in patients with osteoarthritis. Arthritis Rheum. 1999, 42:527-533.
241. Ratcliffe A., Beauvais P.J., Saed-Nejad F. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse. J. Othop. Res. 1994, 12:464-473.
242. Ratcliffe A., Billingham M.E., Saed-Nejad F., Muir H., Hardingham T.E. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. J. Orthop. Res. 1992, 10:350-358.
243. Itano N., Kimata K. Mammalian hyaluronan synthases. IUBMB Life 2002, 54:195-199.
244. Nishida Y., Knudson C.B., Nietfeld J.J., Margulis A., Knudson W. Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly. J. Biol. Chem. 1999, 274:21893-21899.
245. Hiscock D.R., Caterson B., Flannery C.R. Expression of hyaluronan synthases in articular cartilage. Osteoarthritis Cartilage 2000, 8:120-126.
246. Recklies A.D., White C., Melching L., Roughley P.J. Differential regulation and expression of hyaluronan synthases in human articular chondrocytes, synovial cells and osteosarcoma cells. Biochem. J. 2001, 354(Pt 1):17-24.
247. Bodevin-Authelet S., Kusche-Gullberg M., Pummill P.E., DeAngelis P.L., Lindahl U. Biosynthesis of hyaluronan: direction of chain elongation. J. Biol. Chem. 2005, 280:8813-8818. Epub 2004 Dec 28.
248. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A.P., McDonald J.A., Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274:25085-25092.
249. Ng C.K., Handley C.J., Mason R.M., Robinson H.C. Synthesis of hyaluronate in cultured bovine articular cartilage. Biochem. J. 1989, 263:761-767.
250. Holmes M.W.A., Bayliss M.T., Muir H. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem. J. 1988, 250:435-441.
251. El Hajjaji H., Coke A.A., Manicourt D.H. Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH. Arthritis Res. Ther. 2005, 7:R756-R768.
252. Kvam B.J., Fragonas E., Degrassi A., Kavarn C., Matulova M., Pollesello P., Zanetti F., Vittur F. Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. Exp. Cell Res. 1995, 218:79-86.
253. Parsons B., Al-Assaf S., Navaratnam S., Phillips G. Comparison of the reactivity of different reactive oxidative species towards hyaluronan. Hyaluronan 2002, 141-150. MFK Group Ltd, Cambridge, England. J. Kennedy, G. Phillips, P. Williams, V. Hascall (Eds.).
254. Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002, 21:25-29.
255. Knudson C.B., Knudson W. Hyaluronan and CD44: modulators of chondrocyte metabolism. Clin. Orthop. 2004, (427 Suppl):S152-S162.
256. Knudson W., Casey B., Nishida Y., Eger W., Kuettner K.E., Knudson C.B. Hyaluronan oligosaccharides perturb cartilage matrix homeostasis and induce chondrocytic chondrolysis. Arthritis Rheum. 2000, 43:1165-1174.
257. Nishida Y., Knudson C.B., Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage 2004, 12:374-382.
258. Fukuda K., Dan H., Takayama M., Kumano F., Saitoh M., Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J. Pharmacol. Exp. Ther. 1996, 277:1672-1675.
259. Fukuda K., Takayama M., Ueno M., Oh M., Asada S., Kumano F., Tanaka S. Hyaluronic acid inhibits interleukin-1-induced superoxide anion in bovine chondrocytes. Inflamm. Res. 1997, 46:114-117.
260. Homandberg G.A., Hui F., Wen C., Kuettner K.E., Williams J.M. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: I. in vitro. Osteoarthritis Cartilage 1997, 5:309-319.
261. Williams J.M., Zhang J., Kang H., Ummadi V., Homandberg G.A. The effects of hyaluronic acid on fibronectin fragment mediated cartilage chondrolysis in skeletally mature rabbits. Osteoarthritis Cartilage 2003, 11:44-49.
262. Uebelhart D., Williams J.M. Effects of hyaluronic acid on cartilage degradation. Curr. Opin. Rheumatol. 1999, 11:427-435.
263. Altman R.D., Akermark C., Beaulieu A.D., Schnitzer T. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2004, 12:642-649. Durolane International Study Group.
264. Bayliss M.T., Howat S.L., Dudhia J., Murphy J.M., Barry F.P., Edwards J.C., Day A.J. Up-regulation and differential expression of the hyaluronan-binding protein TSG-6 in cartilage and synovium in rheumatoid arthritis and osteoarthritis. Osteoarthritis Cartilage 2001, 9:42-48.
265. Bork P., Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins. J. Mol. Biol. 1999, 231:539-545.
266. Wisniewski H.G., Vilcek J. TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev. 1997, 8:143-156.
267. Solis D., Romero A., Jimenez M., Diaz-Maurino T., Calvete J.J. Binding of mannose-6-phosphate and heparin by boar seminal plasma PSP-II, a member of the spermadhesin protein family. FEBS Lett 1998, 431:273-278.
268. Glant T.T., Kamath R.V., Bardos T., Gal I., Szanto S., Murad Y.M., Sandy J.D., Mort J.S., Roughley P.J., Mikecz K. Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum. 2002, 46:2207-2218.
269. Henrotin Y.E., Bruckner P., Pujol J.P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003, 11:747-755.
270. Amin A.R., Abramson S.B. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol. 1998, 10:263-268.
271. Lyons C.R. The role of nitric oxide in inflammation. Adv. Immunol. 1995, 60:323-371.
272. Aeberhard E.E., Henderson S.A., Arabolos N.S., Griscavage J.M., Castro F.E., Barrett C.T., Ignarro L.J. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem. Biophys. Res. Commun. 1995, 208:1053-1059.
273. Clancy R.M., Gomez P.F., Abramson S.B. Nitric oxide sustains nuclear factor kappaB activation in cytokine-stimulated chondrocytes. Osteoarthritis Cartilage 2004, 12:552-558.
274. Stefanovic-Racic M., Stadler J., Evans C.H. Nitric oxide and arthritis. Arthritis Rheum. 1993, 36:1036-1044.
275. Baddour V.T., Bradley J.D. Clinical assessment and significance of inflammation in knee osteoarthritis. Curr. Rheumatol. Rep. 1999, 1:59-63.
276. Spreng D., Sigrist N., Schweighauser A., Busato A., Schawalder P. Endogenous nitric oxide production in canine osteoarthritis: Detection in urine, serum, and synovial fluid specimens. Vet. Surg. 2001, 30:191-199.
277. Karan A., Karan M.A., Vural P., Erten N., Tascioglu C., Aksoy C., Canbaz M., Oncel A. Synovial fluid nitric oxide levels in patients with knee osteoarthritis. Clin. Rheumatol. 2003, 22:397-399. Epub 2003 Oct 18.
278. Kobayashi K., Matsuzaka S., Yoshida Y., Miyauchi S., Wada Y., Moriya H. The effects of intraarticularly injected sodium hyaluronate on levels of intact aggrecan and nitric oxide in the joint fluid of patients with knee osteoarthritis. Osteoarthritis Cartilage 2004, 12:536-542.
279. Moulton P.J., Goldring M.B., Hancock J.T. NADPH oxidase of chondrocytes contains an isoform of the gp91 phox subunit. Biochem. J. 1998, 329(Pt 3):449-451.
280. Attur M.G., Dave M., Akamatsu M., Katoh M., Amin A.R. Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage 2002, 10:1-4.
281. Sasaki K., Hattori T., Fujisawa T., Takahashi K., Inoue H., Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J. Biochem. (Tokyo) 1995, 123:431-439.
282. Murrell G.A., Jang D., Williams R.J. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem. Biophys. Res. Commun. 1995, 206:15-21.
283. Hickery M.S., Bayliss M.T. Interleukin-1 induced nitric oxide inhibits sulphation of glycosaminoglycan chains in human articular chondrocytes. Biochim. Biophys. Acta 1998, 1425:282-290.
284. Cao M., Westerhausen-Larson A., Niyibizi C., Kavalkovich K., Georgescu H.I., Rizzo C.F., Hebda P.A., Stefanovic-Racic M., Evans C.H. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J. 1997, 324(Pt 1):305-310.
285. Pelletier J.P., Jovanovic D.V., Lascau-Coman V., Femandes J.C., Manning P.T., Connor J.R., Currie M.G. Martel-Pelletier J. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum. 1997, 43:1290-1299.
286. Kurz B., Jost B., Schunke M. Dietary vitamins and selenium diminish the development of mechanically induced osteoarthritis and increase the expression of antioxidative enzymes in the knee joint of STR/1N mice. Osteoarthritis Cartilage 2002, 10:119-126.
287. Studer R.K., Levicoff E., Georgescu H., Miller L., Jaffurs D., Evans C.H. Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRbeta tyrosine phosphorylation. Am. J. Physiol. Cell Physiol. 2000, 279:C961-C969.
288. Del Carlo M., Loeser R.F. Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species. Arthritis Rheum. 2002, 46:394-403.
289. Reiter C.D., Teng R.J., Beckman J.S. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem. 2000, 275:32460-32466.
290. Loeser R.F., Carlson C.S., Del Carlo M., Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage. Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum. 2002, 6:2349-2357.
291. Kwam B.J., Fragonas E., Degrassi A., Kwam C., Matulova M., Pollesello P., Zanetti F., Vittur F. Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. Exp. Cell. Res. 1995, 218:79-86.
292. Johnson K., Vaingankar S., Chen Y., Moffa A., Goldring M.B., Sano K., Jin-Hua P., Sali A., Goding J., Terkeltaub R. Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. Arthritis Rheum. 1999, 42:1986-1997.
293. Ea H.K., Liote F. Calcium pyrophosphate dihydrate and basic calcium phosphate crystal-induced arthropathies: update on pathogenesis, clinical features, and therapy. Curr. Rheumatol. Rep. 2004, 6:221-227.
294. Howell D.S., Martel-Pelletier J., Pelletier J.-P., Morales S., Muniz O. NTP pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage II Further studies on histologic and subcellular distribution. Arthritis Rheum. 1984, 27:193-199.
295. Hirose J., Ryan L.M., Masuda I. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from partients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2002, 46:3218-3229.
296. Sohn P., Crowley M., Slattery E., Serra R. Developmental and TGF-beta-mediated regulation of Ank mRNA expression in cartilage and bone. Osteoarthritis Cartilage 2002, 10:482-490.
297. Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am. J. Physiol. Cell. Physiol. 2001, 281:C1-C11.
298. Hirose J., Masuda J., Ryan L.M. Expression of cartilage intermediate layer protein/nucleotide pyrophosphohydrolase parallels the production of extracellular inorganic pyrophosphate in response to growth factors and with aging. Arthritis Rheum. 2000, 43:2703-2711.
299. Rosenthal A.K., Masuda I., Gohr C.M., Derfus B.A., Le M. The transglutaminase, factor XIIIA, is present in articular chondrocytes. Osteoarthritis Cartilage 2001, 9:578-581.
300. Rosenthal A.K., Mosesson M.W., Gohr C.M., Masuda I., Heinkel D., Seibenlist K.R. Regulation of transglutaminase activity in articular chondrocytes through thrombin receptor-mediated factor XIII synthesis. Thromb. Haemost. 2004, 91:558-568.
301. Johnson K., Hashimoto S., Lotz M., Pritzker K., Terkeltaub R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIa. Am. J. Pathol. 2001, 159:149-163.
302. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse and gene in control of tissue calcification and arthritis. Science 2000, 289(5477):265-270.
303. Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat. Genet. 1998, 19:271-273.
304. Pendleton A., Johnson M.D., Hughes A., Gurley K.A., Ho A.M., Doherty M., Dixey J., Gillet P., Loeuille D., McGrath R., Reginato A., Shiang R., Wright G., Netter P., Williams C., Kingsley D.M. Mutations in ANKH cause chondrocalcinosis. Am. J. Hum. Genet. 2002, 71:933-940. Epub 2002 Sep 20.
305. Williams C.J., Pendleton A., Bonavita G., Reginato A.J., Hughes A.E., Peariso S., Doherty M., McCarty D.J., Ryan L.M. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003, 48:2627-2631.
306. Wendling D., Jeannin-Louys L., Kremer P., Fellmann F., Toussirot E., Mornet E. Adult hypophosphatasia. Current Aspects Joint Bone Spine 2001, 68:120-124.
307. Rosenberg K., Olsson H., Morgelin M., Heinegard D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J. Biol. Chem. 1998, 273:20397-20403.
308. Mabuchi A., Manabe N., Haga N., Kitoh H., Ikeda T., Kawaji H., Tamai K., Hamada J., Nakamura S., Brunetti-Pierri N., Kimizuka M., Takatori Y., Nakamura K., Nishimura G., Ohashi H., Ikegawa S. Novel types of COMP mutations and genotype-phenotype association in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum. Genet. 2003, 112:84-90. Epub 2002 Oct 29.
309. Lorenzo P., Bayliss M.T., Heinegard D. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biol. 2004, 23:381-391.
310. Vilim V., Vytasek R., Olejarova M., Machacek S., Gatterova J., Prochazka B., Kraus V.B., Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001, 9:612-618.
311. Skournal M., Kolarz G., Klingler A. Serum levels of cartilage oligomeric matrix protein A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand. J. Rheumatol. 2003, 32:156-161.
312. Crnkic M., Mansson B., Larsson L., Geborek P., Heinegard D., Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res. Ther. 2003, 5:R181-R185. Epub 2003 Apr 29.
313. Jordan J.M. Cartilage oligomeric matrix protein as a marker of osteoarthritis. Rheumatol. Suppl. 2004, 70:45-49.
314. Manicourt D.H., Poilvache P., Nzeusseu A., van Egeren A., Devogelaer J.P., Lenz M.E., Thonar E.J. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum. 1999, 42:1861-1869.
315. Mundermann A., Dyrby C.O., Andriacchi T.P., King K.B. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis Cartilage 2005, 13:34-38.
316. Bradley K., North J., Saunders D., Schwaeble W., Jeziorska M., Woolley D.E. Synthesis of classical pathway complement components by chondrocytes. Immunology 1996, 88:648-656.
317. Johansen J.S., Olee T., Price P.A., Hashimoto S., Ochs R.L., Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum. 2001, 44:826-837.
318. Johansen J.S., Kirwan J.R., Price P.A., Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand. J. Rheumatol. 2001, 30:297-304.
319. Gendelman R., Burton-Wurster N.I., MacLeod J.N., Lust G. The cartilage-specific fibronectin isoform has a high affinity binding site for the small proteoglycan decorin. J. Biol. Chem. 2003, 278:11175-11181. Epub 2002 Dec.
320. Wolf A., Raiss R.X., Steinmeyer J. Fibronectin metabolism of cartilage explants in response to the frequency of intermittent loading. J. Orthop. Res. 2003, 21:1081-1089.
321. Lust G., Burton-Wurster N. Fibronectin in osteoarthritis: comparison of animal and human diseases. Articular Cartilage and Osteoarthritis 1992, 447-500. Raven Press, New York. K.E. Kuettner, R. Schleyerbach, J.G. Peyron, V.C. Hascall (Eds.).
322. Homundberg G.A., Costa V., Wen C. Fibronectin fragments active in chondrocytic chondrolysis can be chemically cross-linked to the alpha5 integrin receptor subunit. Osteoarthritis Cartilage 2002, 10:938-949.
323. Pichika R., Homandberg G.A. Fibronectin fragments elevate nitric oxide (NO) and inducible NO synthetase (iNOS) levels in bovine cartilage and iNOS inhibitors block fibronectin fragment mediated damage and promote repair. Inflamm. Res. 2004, 53:405-412. Epub 2004 Aug 10.
324. Johnson A., Smith R., Saxne T., Hickery M., Heinegard D. Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures. Osteoarthritis Cartilage 2004, 12:149-159.
325. Homandberg G.A., Hui F. High concentrations of fibronectin fragments cause short-term catabolic effects in cartilage tissue while lower concentrations cause continuous anabolic effects. Archives Biochem. Biophys. 1994, 311:213-218.